For research use only. Not for therapeutic Use.
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids[1][2].
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) (0-100μM; 6 h; HEK293-TB cells) impairs Wnt signaling with IC50 value of 100 nM[1].
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) (1 µM) blocks WNT3A-mediated stabilization of β-catenin in mouse L cells with IC50 value of 50 nM[1].
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) (200 µM; 48 h; LGR5–GFP+ stem cells) disrupts LGR5+ stem cell function[1].
| Catalog Number | I018935 |
| CAS Number | 2247635-23-8 |
| Molecular Formula | C83H114N18O23S2 |
| Purity | ≥95% |
| Reference | [1]. Nile AH, et, al. A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells. Nat Chem Biol. 2018 Jun;14(6):582-590. [2]. Larasati Y, et, al. Unlocking the Wnt pathway: Therapeutic potential of selective targeting FZD7 in cancer. Drug Discov Today. 2022 Mar;27(3):777-792. |
